Common use of PROCEDURES FOR ARQULE COMPOUNDS Clause in Contracts

PROCEDURES FOR ARQULE COMPOUNDS. The parties will screen ArQule Compounds against ACADIA Targets as directed by the Research Committee and described in the Collaboration Plan and Research Plan. Initially, ArQule will not disclose structures of individual ArQule Compounds. ArQule will disclose to ACADIA the structures of Active Compounds that are Available Compounds for ArQule. ACADIA will then determine whether those Active Compounds are Available Compounds for ACADIA. If an Active Compound is an Available Compound for both parties, each party will preserve the availability of the Active Compound and the corresponding ACADIA Target and proceed to confirm activity as described in Section 3.4. and in the Collaboration Plan. In contrast, if a party determines that an Active Compound is not an Available Compound for such party, the parties shall immediately cease all information disclosure and activities under this Agreement with respect to that Active Compound; however, the parties shall use reasonable efforts to monitor whether that Active Compound later becomes an Available Compound and, in such event, shall notify the other party and then proceed in accordance with Section 3.4. Any information regarding the activity of these Active Compounds that are not Available Compounds for the ACADIA Targets shall remain subject to the restrictions on Confidential Information set forth in Article 7.

Appears in 3 contracts

Samples: Discovery Collaboration Agreement (Acadia Pharmaceuticals Inc), Discovery Collaboration Agreement (Arqule Inc), Compound Discovery Collaboration Agreement (Arqule Inc)

AutoNDA by SimpleDocs

PROCEDURES FOR ARQULE COMPOUNDS. The parties Parties will screen ArQule Compounds against ACADIA Targets as directed by the Research Committee and described in the Collaboration Plan and or, as the case may be, the Research Plan. Initially, ArQule will not disclose the structures of individual ArQule Compounds. However, in the case of Compass Array Sets and Mapping Array Libraries, ArQule will disclose the Markush structure of each Compass Array Set and Mapping Array Library as described in the Collaboration Plan. ArQule will disclose to ACADIA GTC the structures of Active Compounds that are Available Compounds for ArQule. ACADIA GTC will then determine whether those Active Compounds are Available Compounds for ACADIAGTC. If an Active Compound is an Available Compound for both partiesParties, each party Party will preserve reserve the availability of the Active Compound. So long as neither Party has notified the other Party that it has withdrawn the GTC Target (if known) as an Available Target before the Active Compound and was detected, each Party will reserve the availability of the corresponding ACADIA GTC Target and (if known). The Parties will then proceed to confirm activity as described in Section 3.4. and in the Collaboration Plan. The Parties shall maintain this reservation on the Available Compound and Available Target (if known) for a period of ***** , subject to extension by the Steering Committee (the "Reservation Period"). In contrast, if a party Party determines that an Active Compound is not an Available Compound for such partyParty, the parties Parties shall immediately cease all information disclosure and activities under this Agreement with respect to that Active Compound; however, the parties shall use reasonable efforts to monitor whether that Active Compound later becomes an Available Compound and, in such event, shall notify the other party and then proceed in accordance with Section 3.4. Any information regarding the activity of these Active Compounds that are not Available Compounds for the ACADIA Targets shall remain subject to the restrictions on Confidential Information set forth in Article 7.

Appears in 1 contract

Samples: Compound Discovery Collaboration Agreement (Genome Therapeutics Corp)

AutoNDA by SimpleDocs
Time is Money Join Law Insider Premium to draft better contracts faster.